To report the clinical results of systemic propranolol for infantile periorbital hemangiomas. Methods: A retrospective analysis was performed on 11 patients who were treated with beta-blockers for cosmetic purposes or for those with an invalid visual axis from January 2010 to June 2017. A beta receptor blocker (propranolol) was administered at a dose of 2 mg/kg/day. The size of the lesion was analyzed using Image J software, version 1.47 (National Institutes of Health, Bethesda, MD, USA) at 1-2 months until the drug was discontinued after the initial treatment and discharge. We observed the occurrence of side effects such as hypoglycemia, nausea, and vomiting due to drug use. Results: Of the 11 patients, 9 (82%) were female and 2 (18%) were male. The location of the capillary hemangioma was in the upper eyelid of eight eyes (72.7%) and in the lower eyelid of three eyes (27.3%). The mean duration of treatment was 6.2 months and the mean follow-up period was 8.3 months. In 11 patients (100%), the lesion size was reduced. A temporary allergic response was seen in one patient, but no adverse side effects were seen that involved life-threatening effects. Conclusions: Infantile hemangiomas may cause cosmetic problems and amblyopia when invading the visual axis, which may require active treatment. Oral beta-blocker therapy for infantile hemangiomas of the orbit was safe for months or longer, with adequate treatment and with little to no adverse effects.
F/U = follow-up; M= male; F = female; LL = lower eyelid; UL = upper eyelid; N = none.
(100%)에서 병변 크기의 감소를 보였다 (Fig. 2, 3 ). 6개월간 
